NanoSyrinx announces closure of its Pre-Seed investment round

The team at NanoSyrinx are delighted to announce our pre-seed financing with an excellent board of investors: MVentures, BioCity and UKI2S.

Our seed round is helping us deliver key scientific milestones as we look to create a revolution in the delivery of biologic molecules in the cell and gene therapy and conventional therapeutic space.

NanoSyrinx is now preparing for its next full seed raise Q4-2020/Q1-2021, so if you’d like to be involved in the next round and join us on our journey, please get in touch!

Full press release details can be found here:
https://www.sciadnewswire.com/news/604/synthetic-biology-start-nanosyrinx-secures-capital-develop-its-fully-customisable-platform

Follow us on social media to stay up to date!

@NanoSyrinx

https://www.linkedin.com/company/nanosyrinx

Read more news

Dr Valentina Galli

NanoSyrinx strengthens senior R&D team

Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development Drug delivery and process development expertise further expands the Company’s R&D capabilities Coventry, UK, 21st January 2025: NanoSyrinx, a synthetic biology company developing Nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, today […]

Read more

Meet our science and scientists at SITC and EORTC

Members from the NanoSyrinx team will be on the road over the coming weeks presenting exciting data from our internal developments and recent collaborations. If you’d like to learn more about our science and meet some of the talented folks responsible for it, come along to the sessions below. A copy of the poster can […]

Read more
Dr Edwin Moses, Chairman NanoSyrinx

NanoSyrinx closes £10 million GBP financing and appoints Dr. Edwin Moses as Chairman

Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind Appointment of Edwin Moses as Chairman to support the leadership team in maximising the value of the technology platform Novel “nanosyringe” platform can deliver complex biologic payloads selectively and […]

Read more
See more news